Urogen Pharma Stock Today
| URGN Stock | USD 11.45 0.38 3.43% |
PerformanceInsignificant
| Odds Of DistressVery High
|
UroGen Pharma is selling at 11.45 as of the 18th of March 2025; that is 3.43 percent increase since the beginning of the trading day. The stock's open price was 11.07. UroGen Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of May 2017 | Category Healthcare | Classification Health Care |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 46.09 M outstanding shares of which 6.19 M shares are at this time shorted by private and institutional investors with about 17.74 trading days to cover. More on UroGen Pharma
Moving together with UroGen Stock
| 0.62 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against UroGen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
UroGen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Elizabeth Barrett | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUroGen Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand UroGen Pharma's financial leverage. It provides some insight into what part of UroGen Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
UroGen Pharma (URGN) is traded on NASDAQ Exchange in USA. It is located in 400 Alexander Park Drive, Princeton, NJ, United States, 08540 and employs 235 people. UroGen Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 510.26 M. UroGen Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 46.09 M outstanding shares of which 6.19 M shares are at this time shorted by private and institutional investors with about 17.74 trading days to cover.
UroGen Pharma currently holds about 111.74 M in cash with (96.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91.
Check UroGen Pharma Probability Of Bankruptcy
Ownership AllocationUroGen Pharma shows a total of 46.09 Million outstanding shares. The majority of UroGen Pharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in UroGen Pharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in UroGen Pharma. Please pay attention to any change in the institutional holdings of UroGen Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check UroGen Ownership Details
UroGen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Diadema Partners Lp | 2024-12-31 | 50 K | |
| Llbh Private Wealth Management, Llc | 2024-12-31 | 39 K | |
| Alps Advisors Inc | 2024-12-31 | 34.1 K | |
| Tidal Investments Llc. | 2024-12-31 | 30.5 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 21.1 K | |
| Vivaldi Capital Management, Llc | 2024-12-31 | 20.1 K | |
| Susquehanna Fundamental Investments, Llc | 2024-12-31 | 19.5 K | |
| Legal & General Group Plc | 2024-09-30 | 15.9 K | |
| Aquatic Capital Management Llc | 2024-12-31 | 9.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.2 M | |
| Vestal Point Capital Lp | 2024-12-31 | 1.6 M |
UroGen Pharma Historical Income Statement
UroGen Stock Against Markets
UroGen Pharma Corporate Management
| Dong Kim | Chief Officer | Profile | |
| Jason JD | Chief Counsel | Profile | |
| Sari PrutchiSagiv | Marketing Director | Profile | |
| Jason Smith | Chief Counsel | Profile | |
| Bryon Wornson | Advocacy Talent | Profile | |
| Eric Zanten | Director Communications | Profile | |
| Christopher CPA | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.